Abstract
The pathogenesis of inflammatory bowel syndrome (IBD), which includes Crohn’s disease (CD) and ulcerative colitis (UC) is poorly understood. However, an inflammatory component is a common hallmark. It has been suggested that CD principally involves Th1 and/or Th17 cells, while UC is considered to be more Th2 driven. Because vasoactive intestinal peptide (VIP) has emerged in the last decade as a putative candidate for the treatment of inflammatory diseases with a Th1 component, it may as well serve as a therapeutic target in CD. In addition, experiments using mice deficient in VIP or its receptors have revealed that the endogenously-produced VIP may participate in the regulation of immunity. The aim of the present review is to summarize the quite considerable array of data which suggests that the VIP-receptor system plays a key role in modulating multiple molecular and cellular players involved in IBD.
Keywords: Crohn’s disease, IBD, inflammation, neuroimmunomodulation, neuropeptide, VIP, Autoimmune diseases, ulcerative colitis (UC), predominant anti-inflammatory action, neuroimmunopeptide, pituitary adenylate cyclaseactivating polypeptide (PACAP), airflow obstruction, airway inflammation.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:VIP in Inflammatory Bowel Disease: State of the Art
Volume: 12 Issue: 4
Author(s): Catalina Abad, Rosa Gomariz, James Waschek, Javier Leceta, Carmen Martinez, Yasmina Juarranz and Alicia Arranz
Affiliation:
Keywords: Crohn’s disease, IBD, inflammation, neuroimmunomodulation, neuropeptide, VIP, Autoimmune diseases, ulcerative colitis (UC), predominant anti-inflammatory action, neuroimmunopeptide, pituitary adenylate cyclaseactivating polypeptide (PACAP), airflow obstruction, airway inflammation.
Abstract: The pathogenesis of inflammatory bowel syndrome (IBD), which includes Crohn’s disease (CD) and ulcerative colitis (UC) is poorly understood. However, an inflammatory component is a common hallmark. It has been suggested that CD principally involves Th1 and/or Th17 cells, while UC is considered to be more Th2 driven. Because vasoactive intestinal peptide (VIP) has emerged in the last decade as a putative candidate for the treatment of inflammatory diseases with a Th1 component, it may as well serve as a therapeutic target in CD. In addition, experiments using mice deficient in VIP or its receptors have revealed that the endogenously-produced VIP may participate in the regulation of immunity. The aim of the present review is to summarize the quite considerable array of data which suggests that the VIP-receptor system plays a key role in modulating multiple molecular and cellular players involved in IBD.
Export Options
About this article
Cite this article as:
Abad Catalina, Gomariz Rosa, Waschek James, Leceta Javier, Martinez Carmen, Juarranz Yasmina and Arranz Alicia, VIP in Inflammatory Bowel Disease: State of the Art, Endocrine, Metabolic & Immune Disorders - Drug Targets 2012; 12 (4) . https://dx.doi.org/10.2174/187153012803832576
DOI https://dx.doi.org/10.2174/187153012803832576 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vitamin D: Evolutionary, Physiological and Health Perspectives
Current Drug Targets Recent Applications of Peanut Phytoalexins
Recent Patents on Food, Nutrition & Agriculture Dietary Lutein and Zeaxanthin in the Prevention of Age-Related Macular Degeneration in the Elderly
Current Nutrition & Food Science Alterations in Plasma Triglyceride Concentrations Following Two Oral Meals with Different Fat Content in Patients with Type 2 Diabetes Mellitus
Current Vascular Pharmacology Heart Valve Lesions In The Antiphospholipid Syndrome
Current Rheumatology Reviews An Update on the Role of the Quality of LDL in Cardiovascular Risk:The Contribution of the Universities of Palermo and Zurich
Recent Patents on Cardiovascular Drug Discovery The Fetal Cardiac Function
Current Cardiology Reviews Pharmacogenomics and Personalized Medicine for the Developing World - Too Soon or Just-in-Time? A Personal View from the World Health Organization
Current Pharmacogenomics and Personalized Medicine Novel Carriers for Coenzyme Q10 Delivery
Current Drug Delivery Transcranial Doppler Ultrasonography: Current Status
Current Medical Imaging Stem Cell-Based Immunomodulation in Type 1 Diabetes: Beyond the Regenerative Approach
Current Pharmaceutical Design PPARγ Activation Improves the Molecular and Functional Components of Ito Remodeling by Angiotensin II
Current Pharmaceutical Design Mechanisms Underlying the Cardiovascular Effects of COX-Inhibition: Benefits and Risks
Current Pharmaceutical Design Potential of Nanocarriers in Genetic Immunization
Recent Patents on Drug Delivery & Formulation Biomarkers in Aortic Valve Stenosis and their Clinical Significance in Transcatheter Aortic Valve Implantation
Current Medicinal Chemistry Ghrelin as a Potential Anti-Obesity Target
Current Pharmaceutical Design Extended-release Formulation Attenuates the Impacts of Fluvastatin on Serum PCSK9 Levels in Humans
Letters in Drug Design & Discovery Hemolysis-Associated Pulmonary Hypertension in Sickle Cell Disease: Global Disruption of the Arginine-Nitric Oxide Pathway
Current Hypertension Reviews Subject Index to Volume 1
Current Vascular Pharmacology Modulating Mesenchymal Stromal Cell Function with Cholesterol Synthesis Inhibitors
Current Medicinal Chemistry